BMS Bids on ImClone
Whether or not BMS's $4.5 billion offer for ImClone is fair is up in the air, but either way BMS stands to gain chunk of change if its bid is approved.
Patients Spurn AIDS Drugs Due to Side Effects
A new study reports that more than 27 percent of Americans are not being treated for HIV because they fear adverse reactions to the drugs. Pharm Exec talked to the doctors in charge of the survey to learn more.
